Literature DB >> 16901074

Juvenile dermatomyositis update.

Carol B Lindsley1.   

Abstract

Recent studies involving juvenile dermatomyositis indicate that the majority of affected children have symptoms suggestive of infection prior to disease onset, damage to skin and muscle each have a distinct pathophysiology, certain urinary muscle metabolites may be useful laboratory markers, and methotrexate used as first line therapy with corticosteroids is associated with greater height velocity and smaller increase in body mass index.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901074     DOI: 10.1007/s11926-996-0022-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  16 in total

1.  Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.

Authors:  Rachel Lynne Smith; Joyce Sundberg; Eli Shamiyah; Alan Dyer; Lauren M Pachman
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

2.  Prolonged QTc interval and juvenile dermatomyositis.

Authors:  B M Fathalla; L C Miller; B Bubolz; J G Schaller
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

3.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

Authors:  Lauren M Pachman; Rebecca Lipton; Rosalind Ramsey-Goldman; Eli Shamiyeh; Kathy Abbott; Eduardo P Mendez; Alan Dyer; Deborah Mc Curdy; Larry Vogler; Ann Reed; Gail Cawkwell; Lawrence Zemel; Christy Sandborg; Rafael Rivas-Chacon; Christine Hom; Norman Ilowite; Abraham Gedalia; Jonathan Gitlin; Michael Borzy
Journal:  Arthritis Rheum       Date:  2005-04-15

Review 4.  Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

Authors:  Adam Huber; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

5.  Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis.

Authors:  Susan M Maillard; Rodney Jones; Catherine M Owens; Clarissa Pilkington; Patricia M Woo; Lucy R Wedderburn; Kevin J Murray
Journal:  Arthritis Rheum       Date:  2005-08-15

6.  Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.

Authors:  Geoffrey R Ambler; Jeffrey Chaitow; Maureen Rogers; David W McDonald; Robert A Ouvrier
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

7.  Pathological calcification in juvenile dermatomyositis (JDM): microCT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures.

Authors:  S Stock; K Ignatiev; P Lee; K Abbott; L Pachman
Journal:  Connect Tissue Res       Date:  2004       Impact factor: 3.417

8.  Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise.

Authors:  Khayriah A Alsufyani; Olivia Ortiz-Alvarez; David A Cabral; Lori B Tucker; Ross E Petty; Helen Nadel; Peter N Malleson
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

9.  HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis.

Authors:  Noriaki Tomono; Masaaki Mori; Shoko Nakajima; Takako Miyamae; Shuichi Ito; Toshihiro Mitsuda; Shumpei Yokota
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

10.  Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis.

Authors:  Carlo Minetti; Marco Gattorno; Silvia Repetto; Andrea Gregorio; Marina Pedemonte; Stefania Assereto; Federico Zara; Claudio Bruno; Alberto Martini
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.